

FABIO BLANDINI

Organization: 1) IRCCS Mondino Foundation, National Institute of Neurology, Pavia
2) Dept. of Brain and Behavioral Sciences, University of Pavia

Current Position: 1) Scientific Director, IRCCS Mondino Foundation;
2) Full Professor of Pharmacology

Address: IRCCS Fondazione Mondino, Istituto Neurologico Nazionale,
via Mondino, 2 - 27100 PAVIA
Tel.: 0382-380416; Fax: 0382-380448
e-mail: fabio.blandini@mondino.it



EDUCATION AND TRAINING

1986 MD, University of Messina, Italy
1987-1990 Specialization in Neurology, University of Messina, Italy
1997-2001 Specialization in Biochemistry and Clinical Chemistry, University of Pavia, Italy

RESEARCH AND PROFESSIONAL EXPERIENCE

1993-1995 Post-doctoral fellow, Dept. of Neurology, University of Rochester Medical Center, Rochester, NY, USA
1995-2010 Head, Laboratory of Functional Neurochemistry, IRCCS Mondino Foundation.
1999-2000 Visiting scientist, Dept. of Neurology, Emory University, Atlanta, USA
2008 Visiting scientist, Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, USA
2009-2016 Head, Neurobiology Research, IRCCS Mondino Foundation
2016-2017 Deputy scientific director (pre-clinical research)
2017- Scientific director, IRCCS Mondino Foundation
2020- Full Professor of Pharmacology, Dept. of Brain and Behavioral Sciences, University of Pavia
2021- Director, Clinical Trial Center, IRCCS Mondino Foundation

APPOINTMENTS & QUALIFICATIONS

2011- Expert, *Agenzia Italiana del Farmaco* (Italian Medicine Agency) and *European Medicine Agency*; CHMP assessor of authorisation applications for Parkinson's disease drugs
2012-2014 Action Group on Experimental Models for Neurodegenerative Diseases, EU Joint Programme on Neurodegenerative Disease Research
<https://www.neurodegenerationresearch.eu/initiatives/jpnd-alignment-actions/animal-and-cell-models/>
2012-2015 Board of the Italian Society for Neuroscience
2017-2020 Board of the Neuroscience Research Hospital Network, Italian Ministry of Health
<https://www.reteneuroscienze.it/en/governance/>
2017- Pan-European Committee, *International Brain Research Organization (IBRO-PERC)*
<https://ibro.org/pan-europe-committee/>
2018- Board of the *European Brain Council*, as IBRO-PERC representative
<https://www.braincouncil.eu/about-us/member-organisations/>

- 2018- Steering Committee of the "European Brain Research Area" project (<https://www.ebra.eu/>)
2018-2020 Committee for Higher Education and Training, *Federation of European Neuroscience Societies* <https://www.fens.org/About-FENS/Governance/Standing--Special-Committees/CHET-Committee/>
2020- Chair, IBRO PERC

TEACHING ACTIVITY

- 2003-2017 Contract professor of Neuropathology, Neurology residency course, University of Pavia
2005-2011 Teacher in the Master course on "Evaluation and control of toxicological risk due to environmental toxins", University of Pavia
2010- Contract professor of Neuropathology, Master degree in Neurobiology, University of Pavia
2020- Full Professor of Pharmacology, University of Pavia

EDITORIAL ACTIVITY

Member of the editorial boards of: 1) *Neurobiology of Disease*; 2) *Frontiers in Cellular Neuroscience*; 3) *Cell Death & Disease*; 4) *Scientific reports*; 5) *CNS & Neurological Disorders - Drug Targets*; 6) *Frontiers in Neuroanatomy*; 7) *Functional Neurology*

RESEARCH ACTIVITY

Translational research in the field of neurodegeneration, with a specific focus on the neurobiology and neuropharmacology of Parkinson's disease, structured in *two major areas*:

A) Basic research

Pathogenesis and pathophysiology of Parkinson's disease

Investigation of neuroanatomical, biomolecular, inflammatory, motor and nonmotor (gastrointestinal) correlates of Parkinson-related neuronal damage; neurotoxicity and neuroprotection in cell cultures exposed to environmental toxins; pathophysiology of motor complications associated with long-term L-Dopa treatment in animal models. Investigation of specific lysosomal dysfunctions (glucocerebrosidase defects) as triggers or facilitators of the neurodegenerative process in Parkinson's disease.

Neuroprotection studies and investigation of potential anti-dyskinetic treatments in animal models of Parkinson's disease

Evaluation of the neuroprotective potential of glutamate antagonists, dopaminergic agonists, MAO-inhibitors, stem cells, lysosomal molecular chaperones, dietary restriction, phytotherapeutics; evaluation of anti-dyskinetic effects of antagonists of glutamate metabotropic receptors.

B) Clinical research

Disease biomarkers

Evaluation of potential biomarkers for early diagnosis and/or follow-up in plasma, blood cells (lymphomonocytes) and skin fibroblasts from patients with sporadic or genetic Parkinson's disease, based on the analysis of intracellular signalling pathways involved in cell damage/death, inflammation mediators, proteasomal and lysosomal function, levels of total and exosome-associated alpha-synuclein. Investigation of mitochondrial and proteolytic dyfunctions as potential biomarkers of aging-related frailty (geriatric syndrome).

Scientific Publications

Author of 172 peer-reviewed publications (PubMed); H-index: 50 (Google Scholar); 42 (Web of Science).